<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33289351</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-0261</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular oncology</Title>
          <ISOAbbreviation>Mol Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical utility of circulating tumor cells: an update.</ArticleTitle>
        <Pagination>
          <StartPage>1647</StartPage>
          <EndPage>1666</EndPage>
          <MedlinePgn>1647-1666</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/1878-0261.12869</ELocationID>
        <Abstract>
          <AbstractText>The prognostic role of circulating tumor cells (CTCs) has been clearly demonstrated in many types of cancer. However, their roles in diagnostic and treatment strategies remain to be defined. In this review, we present an overview of the current clinical validity of CTCs in nonmetastatic and metastatic cancer, and the main studies or concepts investigating the clinical utility of CTCs. In particular, we focus on breast, lung, colorectal, and prostate cancer. Two major topics concerning the clinical utility of CTC are discussed: treatment based on CTC count or CTC variations, and treatment based on the molecular characteristics of CTCs. Although some of these studies are inconclusive, many are still ongoing, and their results could help to define the role of CTCs in the management of cancers. A summary of published or ongoing phase II-III trials is also presented.</AbstractText>
          <CopyrightInformation>© 2020 The Authors. Published by FEBS Press and John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Vasseur</LastName>
            <ForeName>Antoine</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Paris and Saint-Cloud Institut Curie, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kiavue</LastName>
            <ForeName>Nicolas</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Paris and Saint-Cloud Institut Curie, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bidard</LastName>
            <ForeName>François-Clément</ForeName>
            <Initials>FC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Paris and Saint-Cloud Institut Curie, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UVSQ, Paris-Saclay University, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Circulating Tumor Biomarkers laboratory, Inserm CIC-BT 1428, Institut Curie, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pierga</LastName>
            <ForeName>Jean-Yves</ForeName>
            <Initials>JY</Initials>
            <Identifier Source="ORCID">0000-0002-2863-9995</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Paris and Saint-Cloud Institut Curie, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Circulating Tumor Biomarkers laboratory, Inserm CIC-BT 1428, Institut Curie, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Paris University, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cabel</LastName>
            <ForeName>Luc</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Paris and Saint-Cloud Institut Curie, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Circulating Tumor Biomarkers laboratory, Inserm CIC-BT 1428, Institut Curie, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Oncol</MedlineTA>
        <NlmUniqueID>101308230</NlmUniqueID>
        <ISSNLinking>1574-7891</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">CTC-derived xenografts</Keyword>
        <Keyword MajorTopicYN="Y">circulating tumor cells</Keyword>
        <Keyword MajorTopicYN="Y">clinical utility</Keyword>
        <Keyword MajorTopicYN="Y">clinical validity</Keyword>
        <Keyword MajorTopicYN="Y">liquid biopsy</Keyword>
      </KeywordList>
      <CoiStatement>FCB and JYP report research grants from Menarini Silicon Biosystems and FCB reports travel support from Menarini Silicon Biosystems. Other authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>50</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33289351</ArticleId>
        <ArticleId IdType="pmc">PMC8169442</ArticleId>
        <ArticleId IdType="doi">10.1002/1878-0261.12869</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Lozar T, Gersak K, Cemazar M, Kuhar CG, Jesenko T (2019) The biology and clinical potential of circulating tumor cells. Radiol Oncol
53: 2:131–147. 10.2478/raon-2019-0024
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2478/raon-2019-0024</ArticleId>
            <ArticleId IdType="pmc">PMC6572494</ArticleId>
            <ArticleId IdType="pubmed">31104002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ashworth TR (1869) A Case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust
14, 146–147.</Citation>
        </Reference>
        <Reference>
          <Citation>
Boya M, Chu C‐H, Liu R, Ozkaya‐Ahmadov T, Fatih Sarioglu A
et al. (2020) Circulating tumor cell enrichment technologies. In Schaffner F, Merlin J‐L, von Bubnoff N (eds): Tumor Liquid Biopsies Vol. 215, pp. 25–55. Cham: Springer International Publishing.</Citation>
        </Reference>
        <Reference>
          <Citation>
Allard WJ (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res
10, 6897–6904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15501967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kagan M, Howard D, Bendele T, Mayes J, Silvia J, Repollet M, Doyle J, Allard J, Tu N, Bui T
et al. (2002) A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay
25, 104–110.</Citation>
        </Reference>
        <Reference>
          <Citation>
Van Poznak C, Harris LN &amp; Somerfield MR (2015) Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Oncol Pract
11, 514–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29424583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bork U, Rahbari NN, Schölch S, Reissfelder C, Kahlert C, Büchler MW, Weitz J &amp; Koch M (2015) Circulating tumour cells and outcome in non‐metastatic colorectal cancer: a prospective study. Br J Cancer
112, 1306–1313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4402459</ArticleId>
            <ArticleId IdType="pubmed">25867263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gazzaniga P, Gradilone A, de Berardinis E, Busetto GM, Raimondi C, Gandini O, Nicolazzo C, Petracca A, Vincenzi B, Farcomeni A, Gentile V, Cortesi E, Frati L (2012) Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann Oncol
23, 2352–2356. 10.1093/annonc/mdr619
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdr619</ArticleId>
            <ArticleId IdType="pubmed">22351740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Loh J, Jovanovic L, Lehman M, Capp A, Pryor D, Harris M, Nelson C, Martin J (2014) Circulating tumor cell detection in high‐risk non‐metastatic prostate cancer. J Cancer Res Clin Oncol
140, 2157–2162. 10.1007/s00432-014-1775-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-014-1775-3</ArticleId>
            <ArticleId IdType="pubmed">25028119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Magni E, Botteri E, Ravenda PS, Cassatella MC, Bertani E, Chiappa A, Luca F, Zorzino L, Bianchi PP, Adamoli L, Sandri MT, Zampino MG (2014) Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. Int J Colorectal Dis
29, 1053–1059. 10.1007/s00384-014-1958-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00384-014-1958-z</ArticleId>
            <ArticleId IdType="pubmed">25008360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ (2012) EMT and Dissemination Precede Pancreatic Tumor Formation. Cell
148, 349–361. 10.1016/j.cell.2011.11.025
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2011.11.025</ArticleId>
            <ArticleId IdType="pmc">PMC3266542</ArticleId>
            <ArticleId IdType="pubmed">22265420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thalgott M, Rack B, Horn T, Heck MM, Eiber M, Kübler H, Retz M, Gschwend JE, Andergassen U, Nawroth R
et al. (2015) Detection of circulating tumor cells in locally advanced high‐risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy. Anticancer Res
35, 5679–5685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26408743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Van Dalum G, Stam G‐J, Scholten LFA, Mastboom WJB, Vermes I, Tibbe AGJ, De Groot MR, Terstappen LWMM (2015) Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol
46, 1361–1368. 10.3892/ijo.2015.2824
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2015.2824</ArticleId>
            <ArticleId IdType="pubmed">25572133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ilie M, Hofman V, Long‐Mira E, Selva E, Vignaud J‐M, Padovani B, Mouroux J, Marquette C‐H &amp; Hofman P (2014) “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One
9, e111597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4216113</ArticleId>
            <ArticleId IdType="pubmed">25360587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M (2000) Isolation by Size of Epithelial Tumor Cells. Am J Pathol
156, 57–63. 10.1016/s0002-9440(10)64706-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0002-9440(10)64706-2</ArticleId>
            <ArticleId IdType="pmc">PMC1868645</ArticleId>
            <ArticleId IdType="pubmed">10623654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fiorelli A, Accardo M, Carelli E, Angioletti D, Santini M, Di Domenico M (2015) Circulating Tumor Cells in Diagnosing Lung Cancer: Clinical and Morphologic Analysis. Ann Thorac Surg
99, 1899–1905. 10.1016/j.athoracsur.2014.11.049
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.athoracsur.2014.11.049</ArticleId>
            <ArticleId IdType="pubmed">25678504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Marquette C‐H, Boutros J, Benzaquen J, Ferreira M, Pastre J, Pison C, Padovani B, Bettayeb F, Fallet V, Guibert N
et al. (2020) Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. Lancet Respir Med
8, 709–716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32649919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Janni WJ, Rack B, Terstappen LWMM, Pierga J‐Y, Taran F‐A, Fehm T, Hall C, de Groot MR, Bidard F‐C, Friedl TWP (2016) Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clin Cancer Res
22, 2583–2593. 10.1158/1078-0432.ccr-15-1603
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.ccr-15-1603</ArticleId>
            <ArticleId IdType="pubmed">26733614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Franken B, de Groot MR, Mastboom WJB, Vermes I, van der Palen J, Tibbe AGJ &amp; Terstappen LWMM (2012) Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res
14, R133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4053111</ArticleId>
            <ArticleId IdType="pubmed">23088337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM &amp; Krishnamurthy S (2012) Circulating tumour cells in non‐metastatic breast cancer: a prospective study. Lancet Oncol
13, 688–695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22677156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, Friedl TWP, Lorenz R, Tesch H, Fasching PA
et al. (2014) Circulating tumor cells predict survival in early average‐to‐high risk breast cancer patients. J Natl Cancer Inst
106. 10.1093/jnci/dju066
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/dju066</ArticleId>
            <ArticleId IdType="pmc">PMC4112925</ArticleId>
            <ArticleId IdType="pubmed">24832787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Van dalum G, Van der stam GJ, Tibbe AGJ, Franken B, Mastboom WJB, Vermes I, De Groot MR, Terstappen LWMM (2015) Circulating tumor cells before and during follow‐up after breast cancer surgery. Int J Oncol
46, 407–413. 10.3892/ijo.2014.2694
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2014.2694</ArticleId>
            <ArticleId IdType="pubmed">25339612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Novaes M, Bendit I, Garicochea B &amp; del Giglio A (1997) Reverse transcriptase‐polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. Mol Pathol
50, 209–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC379628</ArticleId>
            <ArticleId IdType="pubmed">9350305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S
et al. (2009) Cytokeratin‐19 mRNA‐positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol
27, 2177–2184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19332733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tryfonidis K, Kafousi M, Perraki M, Apostolaki S, Agelaki S, Georgoulias V, Stathopoulos E &amp; Mavroudis D (2014) Detection of circulating cytokeratin‐19 mRNA‐positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer. Clin Breast Cancer
14, 442–450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24958324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S
et al. (2010) Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer
116, 3330–3337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20564098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hall CS, Karhade MG, Bowman Bauldry JB, Valad LM, Kuerer HM, DeSnyder SM, Lucci A (2016) Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients. J Am College Surgeons
223, 20–29. 10.1016/j.jamcollsurg.2016.02.021
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jamcollsurg.2016.02.021</ArticleId>
            <ArticleId IdType="pmc">PMC5868486</ArticleId>
            <ArticleId IdType="pubmed">27049782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goodman CR, Seagle B‐LL, Friedl TWP, Rack B, Lato K, Fink V, Cristofanilli M, Donnelly ED, Janni W, Shahabi S
et al. (2018) Association of circulating tumor cell status with benefit of radiotherapy and survival in early‐stage breast cancer. JAMA Oncol
4, e180163–e180163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6143053</ArticleId>
            <ArticleId IdType="pubmed">29800954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sparano J, O’Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, Sledge GW &amp; Miller KD (2018) Association of circulating tumor cells with late recurrence of estrogen receptor‐positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol
4, 1700–1706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6385891</ArticleId>
            <ArticleId IdType="pubmed">30054636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bidard F‐C, Michiels S, Riethdorf S, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J
et al. (2018) Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta‐analysis. J Nat Cancer Inst
110, 560–567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29659933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thery L, Meddis A, Cabel L, Proudhon C, Latouche A, Pierga J‐Y, Bidard F‐C (2019) Circulating Tumor Cells in Early Breast Cancer. JNCI Cancer Spectrum
3, 10.1093/jncics/pkz026
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jncics/pkz026</ArticleId>
            <ArticleId IdType="pmc">PMC6649836</ArticleId>
            <ArticleId IdType="pubmed">31360902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V, Grávalos C, Escudero P, Vera R, Aranda E (2015) Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol
26, 535–541. 10.1093/annonc/mdu568
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdu568</ArticleId>
            <ArticleId IdType="pubmed">25515656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lu C‐Y, Tsai H‐L, Uen Y‐H, Hu H‐M, Chen C‐W, Cheng T‐L, Lin S‐R, Wang J‐Y (2013) Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br J Cancer
108, 791–797. 10.1038/bjc.2012.595
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2012.595</ArticleId>
            <ArticleId IdType="pmc">PMC3590657</ArticleId>
            <ArticleId IdType="pubmed">23422758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lu Y‐J, Wang P, Peng J, Wang X, Zhu Y‐W, Shen N (2017) Meta‐analysis Reveals the Prognostic Value of Circulating Tumour Cells Detected in the Peripheral Blood in Patients with Non‐Metastatic Colorectal Cancer. Sci Rep
7, 10.1038/s41598-017-01066-y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-01066-y</ArticleId>
            <ArticleId IdType="pmc">PMC5430457</ArticleId>
            <ArticleId IdType="pubmed">28424486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB (2013) Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol
24, 2057–2061. 10.1093/annonc/mdt176
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdt176</ArticleId>
            <ArticleId IdType="pubmed">23676420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A (2012) A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer
106, 508–516. 10.1038/bjc.2011.545
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2011.545</ArticleId>
            <ArticleId IdType="pmc">PMC3273340</ArticleId>
            <ArticleId IdType="pubmed">22187035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhu W‐F, Li J, Yu L‐C, Wu Y, Tang X‐P, Hu Y‐M, Chen Y‐C (2014) Prognostic value of EpCAM/MUC1 mRNA‐positive cells in non‐small cell lung cancer patients. Tumor Biol
35, 1211–1219. 10.1007/s13277-013-1162-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-013-1162-8</ArticleId>
            <ArticleId IdType="pubmed">24061641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bayarri‐Lara C, Ortega FG, Cueto Ladrón de Guevara A, Puche JL, Ruiz Zafra J, de Miguel‐Pérez D, Ramos AS‐P, Giraldo‐Ospina CF, Navajas Gómez JA (2016) Circulating Tumor Cells Identify Early Recurrence in Patients with Non‐Small Cell Lung Cancer Undergoing Radical Resection. PLOS ONE
11, e0148659. 10.1371/journal.pone.0148659
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0148659</ArticleId>
            <ArticleId IdType="pmc">PMC4767413</ArticleId>
            <ArticleId IdType="pubmed">26913536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, Flejou JF, Lantuejoul S, Piaton E, Mourad N, Butori C (2011) Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker. Clin Cancer Res
17, 827–835. 10.1158/1078-0432.ccr-10-0445
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.ccr-10-0445</ArticleId>
            <ArticleId IdType="pubmed">21098695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yoon SO, Kim YT, Jung KC, Jeon YK, Kim B‐H, Kim C‐W (2011) TTF‐1 mRNA‐positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non‐small cell lung cancer patients. Lung Cancer
71, 209–216. 10.1016/j.lungcan.2010.04.017
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2010.04.017</ArticleId>
            <ArticleId IdType="pubmed">20471712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hoshimoto S, Shingai T, Morton DL, Kuo C, Faries MB, Chong K, Elashoff D, Wang H‐J, Elashoff RM, Hoon DSB (2012) Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial. J Clin Oncol
30, 3819–3826. 10.1200/jco.2011.40.0887
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2011.40.0887</ArticleId>
            <ArticleId IdType="pmc">PMC3478576</ArticleId>
            <ArticleId IdType="pubmed">23008288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mocellin S, Del Fiore P, Guarnieri L, Scalerta R, Foletto M, Chiarion V, Pilati P, Nitti D, Lise M, Rossi CR (2004) Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high‐risk cutaneous melanoma. Int J Cancer
111, 741–745. 10.1002/ijc.20347
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.20347</ArticleId>
            <ArticleId IdType="pubmed">15252844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Inhestern J, Oertel K, Stemmann V, Schmalenberg H, Dietz A, Rotter N, Veit J, Görner M, Sudhoff H, Junghanß C, et al. (2015) Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer. PLOS ONE
10, e0132901. 10.1371/journal.pone.0132901
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0132901</ArticleId>
            <ArticleId IdType="pmc">PMC4505900</ArticleId>
            <ArticleId IdType="pubmed">26186556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nasta y P, Ruf C, Becker P, Bednarz‐Knoll N, Stoupiec M, Kavsur R, Isbarn H, Matthies C, Wagner W, Hoppner D, et al. (2014) Circulating Tumor Cells in Patients with Testicular Germ Cell Tumors. Clin Cancer Res
20, 3830–3841. 10.1158/1078-0432.ccr-13-2819
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.ccr-13-2819</ArticleId>
            <ArticleId IdType="pubmed">24634372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez‐Espinoza R, Anand A, Koscuiszka M, Väänänen R‐M, Pettersson K, Chun FK‐H
et al. (2009) Circulating Prostate Tumor Cells Detected by Reverse Transcription‐PCR in Men with Localized or Castration‐Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival. Clin Chem
55, 765–773. 10.1373/clinchem.2008.117952
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1373/clinchem.2008.117952</ArticleId>
            <ArticleId IdType="pmc">PMC2782624</ArticleId>
            <ArticleId IdType="pubmed">19233911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yates DR, Rouprêt M, Drouin SJ, Comperat E, Ricci S, Lacave R, Sèbe P, Cancel‐Tassin G, Bitker M‐O, Cussenot O (2012) Quantitative RT‐PCR analysis of PSA and prostate‐specific membrane antigen mRNA to detect circulating tumor cells improves recurrence‐free survival nomogram prediction after radical prostatectomy. The Prostate
72, 1382–1388. 10.1002/pros.22488
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pros.22488</ArticleId>
            <ArticleId IdType="pubmed">22228175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bissolati M, Sandri MT, Burtulo G, Zorzino L, Balzano G, Braga M (2015) Portal vein‐circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer. Tumor Biol
36, 991–996. 10.1007/s13277-014-2716-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-014-2716-0</ArticleId>
            <ArticleId IdType="pubmed">25318603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crosbie PAJ, Shah R, Krysiak P, Zhou C, Morris K, Tugwood J, Booton R, Blackhall F, Dive C (2016) Circulating Tumor Cells Detected in the Tumor‐Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. J Thorac Oncol
11, 1793–1797. 10.1016/j.jtho.2016.06.017
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2016.06.017</ArticleId>
            <ArticleId IdType="pmc">PMC5063509</ArticleId>
            <ArticleId IdType="pubmed">27468936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chemi, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA, Jamal‐Hanjani M, Birkbak N
et al. (2019) Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nature Med
25, 1534–1539. 10.1038/s41591-019-0593-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0593-1</ArticleId>
            <ArticleId IdType="pmc">PMC6986897</ArticleId>
            <ArticleId IdType="pubmed">31591595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LWMM, Hayes DF (2004) Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. New England J Med
351, 781–791. 10.1056/nejmoa040766
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa040766</ArticleId>
            <ArticleId IdType="pubmed">15317891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC
et al. (2008) Relationship of Circulating Tumor Cells to Tumor Response, Progression‐Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer. J Clin Oncol
26, 3213–3221. 10.1200/jco.2007.15.8923
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2007.15.8923</ArticleId>
            <ArticleId IdType="pubmed">18591556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LWWM, Pienta KJ, Raghavan D (2008) Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration‐Resistant Prostate Cancer. Clin Cancer Res
14, 6302–6309. 10.1158/1078-0432.ccr-08-0872
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.ccr-08-0872</ArticleId>
            <ArticleId IdType="pubmed">18829513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC
et al. (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. JCO
23, 1420–1430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15735118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bidard F‐C, Peeters DJ, Fehm T, Nolé F, Gisbert‐Criado R, Mavroudis D, Grisanti S, Generali D, Garcia‐Saenz JA, Stebbing J
et al. (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol
15, 406–414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24636208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Helissey C, Berger F, Cottu P, Diéras V, Mignot L, Servois V, Bouleuc C, Asselain B, Pelissier S, Vaucher I
et al. (2015) Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. Cancer Lett
360, 213–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25700777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga J‐Y
et al. (2020) Serial analysis of circulating tumor cells in metastatic breast cancer receiving first‐line chemotherapy. J Natl Cancer Inst
10.1093/jnci/djaa113
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djaa113</ArticleId>
            <ArticleId IdType="pmc">PMC8023821</ArticleId>
            <ArticleId IdType="pubmed">32770247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, Xu H &amp; Wang Z (2015) Meta‐analysis of the prognostic value of circulating tumor cells detected with the Cell Search System in colorectal cancer. BMC Cancer
15, 202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4389311</ArticleId>
            <ArticleId IdType="pubmed">25880692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hardingham JE, Grover P, Winter M, Hewett PJ, Price TJ &amp; Thierry B (2015) Detection and clinical significance of circulating tumor cells in colorectal cancer–20 years of progress. Mol Med
21 (Suppl 1), S25–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4661051</ArticleId>
            <ArticleId IdType="pubmed">26605644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Steinert G, Schölch S, Koch M &amp; Weitz J (2012) Biology and significance of circulating and disseminated tumour cells in colorectal cancer. Langenbecks Arch Surg
397, 535–542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22350614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Krebs MG, Renehan AG, Backen A, Gollins S, Chau I, Hasan J, Valle JW, Morris K, Beech J, Ashcroft L
et al. (2015) Circulating tumor cell enumeration in a phase II trial of a four‐drug regimen in advanced colorectal cancer. Clin Colorectal Cancer
14, 115–122.e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25680623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C
et al. (2017) Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. Eur J Cancer
79, 15–22. 10.1016/j.ejca.2017.03.036
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2017.03.036</ArticleId>
            <ArticleId IdType="pubmed">28456090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA
et al. (2014) Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration‐Resistant Prostate Cancer. J Clin Onco
32, 1136–1142. 10.1200/jco.2013.51.7417
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2013.51.7417</ArticleId>
            <ArticleId IdType="pmc">PMC3970171</ArticleId>
            <ArticleId IdType="pubmed">24616308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Okegawa T, Itaya N, Hara H, Tambo M, Nutahara K (2014) Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration‐resistant prostate cancer. Anticancer Res
34, 6705–6710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25368278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD
et al. (2017) Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration‐resistant Prostate Cancer. Eur Urol
71, 168–171. 10.1016/j.eururo.2016.07.051
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eururo.2016.07.051</ArticleId>
            <ArticleId IdType="pubmed">27522164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med
8, 431–440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2727467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R
et al. (2015) Circulating Tumor Cell Biomarker Panel As an Individual‐Level Surrogate for Survival in Metastatic Castration‐Resistant Prostate Cancer. J Clin Oncol
33, 1348–1355. 10.1200/jco.2014.55.3487
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2014.55.3487</ArticleId>
            <ArticleId IdType="pmc">PMC4397279</ArticleId>
            <ArticleId IdType="pubmed">25800753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hou J‐M, Krebs MG, Lancashire L, Sloane R, Backen A, Swain K‐R, Priest J‐CL, Greystoke A, Zhou C, Morris K
et al. (2012) Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small‐cell lung cancer. J Clin Oncol
30, 525–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22253462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lindsay CR, Blackhall FH, Carmel A, Fernandez‐Gutierrez F, Gazzaniga P, Groen HJM, Hiltermann TJN, Krebs MG, Loges S, López‐López R
et al. (2019) EPAC‐lung: pooled analysis of circulating tumour cells in advanced non‐small cell lung cancer. Eur J Cancer
117, 60–68. 10.1016/j.ejca.2019.04.019
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2019.04.019</ArticleId>
            <ArticleId IdType="pubmed">31254940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Krebs MG, Sloane R, Priest L, Lancashire L, Hou J‐M, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G
et al. (2011) Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small‐Cell Lung Cancer. J Clin Oncol
29, 1556–1563. 10.1200/jco.2010.28.7045
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2010.28.7045</ArticleId>
            <ArticleId IdType="pubmed">21422424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BGM, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR
et al. (2012) Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non‐Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib. Clin Cancer Res
18, 2391–2401. 10.1158/1078-0432.ccr-11-3148
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.ccr-11-3148</ArticleId>
            <ArticleId IdType="pubmed">22492982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cabel L, Proudhon C, Mariani P, Tzanis D, Beinse G, Bieche I, Pierga J‐Y &amp; Bidard F‐C (2017) Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?
Eur J Surg Oncol
43, 949–962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28185687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M &amp; Barrett JC (2015) EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross‐platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer
90, 509–515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26494259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R
et al. (2018) Liquid biopsy for advanced Non‐Small Cell Lung Cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol
13, 1248–1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29885479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Morrow CJ, Trapani F, Metcalf RL, Bertolini G, Hodgkinson CL, Khandelwal G, Kelly P, Galvin M, Carter L, Simpson KL
et al. (2016) Tumourigenic non‐small‐cell lung cancer mesenchymal circulating tumour cells: a clinical case study. Ann Oncol
27, 1155–1160. 10.1093/annonc/mdw122
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdw122</ArticleId>
            <ArticleId IdType="pmc">PMC4880063</ArticleId>
            <ArticleId IdType="pubmed">27013395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW
et al. (2008) Detection of Mutations inEGFRin Circulating Lung‐Cancer Cells. New England J Med
359, 366–377. 10.1056/nejmoa0800668
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa0800668</ArticleId>
            <ArticleId IdType="pmc">PMC3551471</ArticleId>
            <ArticleId IdType="pubmed">18596266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pailler E, Auger N, Lindsay CR, Vielh P, Islas‐Morris‐Hernandez A, Borget I, Ngo‐Camus M, Planchard D, Soria J‐C, Besse B, Farace F
et al. (2015) High level of chromosomal instability in circulating tumor cells of ROS1‐rearranged non‐small‐cell lung cancer. Ann Oncol
26, 1408–1415. 10.1093/annonc/mdv165
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdv165</ArticleId>
            <ArticleId IdType="pmc">PMC4478971</ArticleId>
            <ArticleId IdType="pubmed">25846554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pailler E, Adam J, Barthélémy A, Oulhen M, Auger N, Valent A, Borget I, Planchard D, Taylor M, André F
et al. (2013) Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK‐Positive Non–Small‐Cell Lung Cancer. J Clin Oncol
31, 2273–2281. 10.1200/jco.2012.44.5932
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2012.44.5932</ArticleId>
            <ArticleId IdType="pubmed">23669222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hayes D, Walker T, Singh B, Vitetta E, Uhr J, Gross S, Rao C, Doyle G, Terstappen L (2002) Monitoring expression of HER‐2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol
21, 1111–1117. 10.3892/ijo.21.5.1111
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.21.5.1111</ArticleId>
            <ArticleId IdType="pubmed">12370762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fehm T, Becker S, Duerr‐Stoerzer S, Sotlar K, Mueller V, Wallwiener D, Lane N, Solomayer E &amp; Uhr J (2007) Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res
9, R74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2242672</ArticleId>
            <ArticleId IdType="pubmed">17963511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona S, Biganzoli L, Giannini A &amp; Di Leo A (2009) Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat
118, 523–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19597704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nanou A, Zeune LL, Bidard F‐C, Pierga J‐Y &amp; Terstappen LWMM (2020) HER2 expression on tumor‐derived extracellular vesicles and circulating tumor cells in metastatic breast cancer. Breast Cancer Res
22, 86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7424685</ArticleId>
            <ArticleId IdType="pubmed">32787900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B
et al. (2010) HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat
124, 403–412. 10.1007/s10549-010-1163-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-010-1163-x</ArticleId>
            <ArticleId IdType="pubmed">20859679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liedtke C, Broglio K, Moulder S, Hsu L, Kau S‐W, Symmans WF, Albarracin C, Meric‐Bernstam F, Woodward W, Theriault RL
et al. (2009) Prognostic impact of discordance between triple‐receptor measurements in primary and recurrent breast cancer. Ann Oncol
20, 1953–1958. 10.1093/annonc/mdp263
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdp263</ArticleId>
            <ArticleId IdType="pmc">PMC2791352</ArticleId>
            <ArticleId IdType="pubmed">19596702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schneck H, Blassl C, Meier‐Stiegen F, Neves RP, Janni W, Fehm T, Neubauer H
et al. (2013) Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol Oncol
7, 976–986. 10.1016/j.molonc.2013.07.007
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2013.07.007</ArticleId>
            <ArticleId IdType="pmc">PMC5528457</ArticleId>
            <ArticleId IdType="pubmed">23895914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, Pazzagli M, Di Leo A, Pinzani P
et al. (2015) Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol
9, 749–757. 10.1016/j.molonc.2014.12.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2014.12.001</ArticleId>
            <ArticleId IdType="pmc">PMC5528771</ArticleId>
            <ArticleId IdType="pubmed">25539732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tzanikou E, Markou A, Politaki E, Koutsopoulos A, Psyrri A, Mavroudis D, Georgoulias V, Lianidou E (2019) PIK3 CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. Mol Oncol
13, 2515–2530. 10.1002/1878-0261.12540
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12540</ArticleId>
            <ArticleId IdType="pmc">PMC6887588</ArticleId>
            <ArticleId IdType="pubmed">31254443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B (2019) Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England J Med
380, 1929–1940. 10.1056/nejmoa1813904
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa1813904</ArticleId>
            <ArticleId IdType="pubmed">31091374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL
et al. (2014) AR‐V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. New England J Med
371, 1028–1038. 10.1056/nejmoa1315815
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa1315815</ArticleId>
            <ArticleId IdType="pmc">PMC4201502</ArticleId>
            <ArticleId IdType="pubmed">25184630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, McLaughlin B, Lu D, Fleisher M, Orr S, Lowes L
et al. (2018) Assessment of the validity of nuclear‐localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration‐resistant prostate cancer. JAMA Oncol
4, 1179–1186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6139066</ArticleId>
            <ArticleId IdType="pubmed">29955787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maurer T, Schwamborn K, Schottelius M, Wester H‐J, Schwaiger M, Gschwend JE &amp; Eiber M (2016) PSMA theranostics using PET and subsequent radioguided surgery in recurrent prostate cancer. Clin Genitourin Cancer
14, e549–e552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27318956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ristau BT, O’Keefe DS &amp; Bacich DJ (2014) The prostate‐specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol
32, 272–279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3972351</ArticleId>
            <ArticleId IdType="pubmed">24321253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG
et al. (2018) [177Lu]‐PSMA‐617 radionuclide treatment in patients with metastatic castration‐resistant prostate cancer (LuPSMA trial): a single‐centre, single‐arm, phase 2 study. Lancet Oncol
19, 825–833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29752180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Autio KA, Dreicer R, Anderson J, Garcia JA, Alva Aj, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP
et al. (2018) Safety and efficacy of BIND‐014, a docetaxel nanoparticle targeting prostate‐specific membrane antigen for patients with metastatic castration‐resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol
4, 1344–1351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6233779</ArticleId>
            <ArticleId IdType="pubmed">29978216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Philips GK &amp; Atkins M (2015) Therapeutic uses of anti‐PD‐1 and anti‐PD‐L1 antibodies. Int Immunol
27, 39–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25323844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Boffa DJ, Graf RP, Salazar MC, Hoag J, Lu D, Krupa R, Louw J, Dugan L, Wang Y, Landers M
et al. (2017) Cellular expression of PD‐L1 in the peripheral blood of lung cancer patients is associated with worse survival. Cancer Epidemiol Biomarkers Prev
26, 1139–1145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5500408</ArticleId>
            <ArticleId IdType="pubmed">28446544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jacot W, Mazel M, Mollevi C, Pouderoux S, D’Hondt V, Cayrefourcq L, Bourgier C, Boissiere‐Michot F, Berrabah F, Lopez‐Crapez E
et al. (2020) Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. Clin Chem
66, 1093–1101. 10.1093/clinchem/hvaa121
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/clinchem/hvaa121</ArticleId>
            <ArticleId IdType="pubmed">32712650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T &amp; Alix‐Panabières C (2015) Frequent expression of PD‐L1 on circulating breast cancer cells. Mol Oncol
9, 1773–1782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5528721</ArticleId>
            <ArticleId IdType="pubmed">26093818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yue C, Jiang Y, Li P, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T &amp; Alix‐Panabières C
et al. (2018) Dynamic change of PD‐L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD‐1 blockade therapy. Oncoimmunology
7, e1438111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5993493</ArticleId>
            <ArticleId IdType="pubmed">29900038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hofman P, Heeke S, Alix‐Panabières C &amp; Pantel K (2019) Liquid biopsy in the era of immuno‐oncology: is it ready for prime‐time use for cancer patients?
Ann Oncol
30, 1448–1459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31228184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, Mastromartino M, del Bene G, Prete A, Longo F
et al. (2016) Monitoring PD‐L1 positive circulating tumor cells in non‐small cell lung cancer patients treated with the PD‐1 inhibitor Nivolumab. Sci Rep
6, 31726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4995431</ArticleId>
            <ArticleId IdType="pubmed">27553175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Janning M, Kobus F, Babayan A, Wikman H, Velthaus JL, Bergmann S, Schatz S, Falk M, Berger LA, Böttcher LM
et al. (2019) Determination of PD‐L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD‐1/PD‐L1 Inhibitors. Cancers
11:835. 10.3390/cancers11060835
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11060835</ArticleId>
            <ArticleId IdType="pmc">PMC6627043</ArticleId>
            <ArticleId IdType="pubmed">31212989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching PA, Brain E
et al. (2018) Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091‐10093, BIG 1‐12, Treat CTC): a randomized phase II trial. Ann Oncol
29, 1777–1783. 10.1093/annonc/mdy211
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy211</ArticleId>
            <ArticleId IdType="pubmed">29893791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Paik S, Kim C &amp; Wolmark N (2008) HER2 Status and benefit from adjuvant Trastuzumab in breast cancer. N Engl J Med
358, 1409–1411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18367751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fehrenbacher L, Cecchini RS, Geyer Jr CE, Rastogi P, Costantino JP, Atkins JN, Crown JP, Polikoff J, Boileau JF, Provencher L
et al. (2020) NSABP B‐47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High‐Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. J Clin Oncol
38, 444–453. 10.1200/jco.19.01455
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.19.01455</ArticleId>
            <ArticleId IdType="pmc">PMC7007289</ArticleId>
            <ArticleId IdType="pubmed">31821109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland‐Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA (2014) Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. J Clin Oncol
32, 3483–3489. 10.1200/jco.2014.56.2561
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2014.56.2561</ArticleId>
            <ArticleId IdType="pmc">PMC4209100</ArticleId>
            <ArticleId IdType="pubmed">24888818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bidard F‐C &amp; Pierga J‐Y (2015) Clinical utility of circulating tumor cells in metastatic breast cancer. JCO
33, 1622–1622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25870091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bidard FC, Asselain B, Baffert S, Brain E, Campone M, Delaloge S, Bachelot T, Tubiana‐Mathieu N, Pelissier S, Pierga JY
et al. (2012:OT3‐4‐05‐OT3‐4–05) Abstract OT3‐4‐05: Use of early CIRculating tumor CElls count changes to guide the use of chemotherapy in advanced metastatic breast cancer patients: the CirCe01 randomized trial. Ongoing Trials Poster Session Abstracts. American Association for Cancer Research.</Citation>
        </Reference>
        <Reference>
          <Citation>
Cabel L, Berger F, Cottu P, Loirat D, Rampanou A, Brain E, Cyrille S, Bourgeois H, Kiavue N, Deluche E, Ladoire S
et al. (2020) Clinical utility of circulating tumor cell‐based monitoring of late‐line chemotherapy for metastatic breast cancer: the randomized CirCe01 trial. Br J Cancer. (accepted).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8007590</ArticleId>
            <ArticleId IdType="pubmed">33473163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bidard FC, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E, Bachelot T, Bourgeois H, Gonçalves A, Ladoire S
et al. (2020) Efficacy of Circulating Tumor Cell Count–Driven vs Clinician‐Driven First‐line Therapy Choice in Hormone Receptor–Positive, ERBB2‐Negative Metastatic Breast Cancer. JAMA Oncol.
10.1001/jamaoncol.2020.5660
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2020.5660</ArticleId>
            <ArticleId IdType="pmc">PMC7645742</ArticleId>
            <ArticleId IdType="pubmed">33151266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch‐Shimon S, Campone M, Blackwell KL, André F, Winer EP
et al. (2016) Ribociclib as First‐Line Therapy for HR‐Positive, Advanced Breast Cancer. New England J Med
375, 1738–1748. 10.1056/nejmoa1609709
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa1609709</ArticleId>
            <ArticleId IdType="pubmed">27717303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Aranda E, Viéitez JM, Gómez‐España A, Gil Calle S, Salud‐Salvia A, Graña B, Garcia‐Alfonso P, Rivera F, Quintero‐Aldana GA, Reina‐Zoilo JJ (2020) FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ‐1 trial. ESMO Open
5, e000944. 10.1136/esmoopen-2020-000944
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/esmoopen-2020-000944</ArticleId>
            <ArticleId IdType="pmc">PMC7640586</ArticleId>
            <ArticleId IdType="pubmed">33148620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, Ravaioli A, Gianni L, Di Marsico R, Tondini C
et al. (2012) Final results of a multicenter phase II clinical trial evaluating the activity of single‐agent lapatinib in patients with HER2‐negative metastatic breast cancer and HER2‐positive circulating tumor cells. A proof‐of‐concept study. Breast Cancer Res Treat
134, 283–289. 10.1007/s10549-012-2045-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-012-2045-1</ArticleId>
            <ArticleId IdType="pubmed">22476856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jacot W, Cottu P, Berger F, Dubot C, Venat‐Bouvet L, Lortholary A, Bourgeois H, Bollet M, Servent V, Luporsi E
et al. (2019) Actionability of HER2‐amplified circulating tumor cells in HER2‐negative metastatic breast cancer: the CirCe T‐DM1 trial. Breast Cancer Res
21, 10.1186/s13058-019-1215-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13058-019-1215-z</ArticleId>
            <ArticleId IdType="pmc">PMC6854749</ArticleId>
            <ArticleId IdType="pubmed">31727113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Krause S, Friedl T, Romashova T, Fasching PA, Schneeweiss A, Müller V, Taran FA, Arkadius P, Marie T, De Gregorio A
et al. (2019) Abstract OT1‐10‐01: DETECT III/IV study trial – The multicenter study program in patients with HER2‐negative metastatic breast cancer and circulating tumor cells. Ongoing Clinical Trials, American Association for Cancer Research. OT1‐10‐01‐OT1‐10–01</Citation>
        </Reference>
        <Reference>
          <Citation>
Schramm A, Friedl TWP, Schochter F, Scholz C, de Gregorio N, Huober J, Rack B, Trapp E, Alunni‐Fabbroni M, Müller V
et al. (2016) Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet
293, 271–281. 10.1007/s00404-015-3879-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00404-015-3879-7</ArticleId>
            <ArticleId IdType="pubmed">26354331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR
et al. (2015) Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration‐Resistant Prostate Cancer. JAMA Oncol
1, 582. 10.1001/jamaoncol.2015.1341
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2015.1341</ArticleId>
            <ArticleId IdType="pmc">PMC4537351</ArticleId>
            <ArticleId IdType="pubmed">26181238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ
et al. (2019) Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High‐Risk Castration‐Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol
37, 1120–1129. 10.1200/jco.18.01731
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.18.01731</ArticleId>
            <ArticleId IdType="pmc">PMC6494355</ArticleId>
            <ArticleId IdType="pubmed">30865549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pantel K, Hille C &amp; Scher HI (2019) Circulating tumor cells in prostate cancer: from discovery to clinical utility. Clin Chem
65, 87–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30602476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Friedman R (2016) Drug resistance in cancer: molecular evolution and compensatory proliferation. Oncotarget
7, 11746–11755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4914245</ArticleId>
            <ArticleId IdType="pubmed">26909596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McGranahan N &amp; Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell
168, 613–628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28187284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J
et al. (2015) RNA‐Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science
349, 1351–1356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4872391</ArticleId>
            <ArticleId IdType="pubmed">26383955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R
et al. (2016) HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature
537, 102–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5161614</ArticleId>
            <ArticleId IdType="pubmed">27556950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD
et al. (2020) Single‐cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small‐cell lung cancer. Nature Cancer
1, 423–436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7842382</ArticleId>
            <ArticleId IdType="pubmed">33521652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T
et al. (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnol
31, 539–544. 10.1038/nbt.2576
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.2576</ArticleId>
            <ArticleId IdType="pubmed">23609047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Klameth L, Rath B, Hochmaier M, Moser D, Redl M, Mungenast F, Gelles K, Ulsperger E, Zeillinger R &amp; Hamilton G (2017) Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance. Sci Rep
7, 5337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5509650</ArticleId>
            <ArticleId IdType="pubmed">28706293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kolostova K, Cegan M &amp; Bobek V (2014) Circulating tumour cells in patients with urothelial tumours: Enrichment and in vitro culture. Can Urol Assoc J
8, E715–720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4216304</ArticleId>
            <ArticleId IdType="pubmed">25408812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Soler A, Cayrefourcq L, Mazard T, Babayan A, Lamy P‐J, Assou S, Assenat E, Pantel K &amp; Alix‐Panabières C (2018) Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy‐driven tumor changes. Sci Rep
8, 15931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6206091</ArticleId>
            <ArticleId IdType="pubmed">30374140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tayoun T, Faugeroux V, Oulhen M, Aberlenc A, Pawlikowska P, Farace F
et al. (2019) CTC‐Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs). Cells
8, 1145. 10.3390/cells8101145
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8101145</ArticleId>
            <ArticleId IdType="pmc">PMC6829286</ArticleId>
            <ArticleId IdType="pubmed">31557946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D, Goodman JC, Groves MD &amp; Marchetti D (2013) The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med
5, 180ra48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3863909</ArticleId>
            <ArticleId IdType="pubmed">23576814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z
et al. (2014) Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science
345, 216–220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4358808</ArticleId>
            <ArticleId IdType="pubmed">25013076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K
et al. (2014) Tumorigenicity and genetic profiling of circulating tumor cells in small‐cell lung cancer. Nature Medicine
20, 897–903. 10.1038/nm.3600
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3600</ArticleId>
            <ArticleId IdType="pubmed">24880617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hainsworth JD, Murphy PB, Alemar JR, Daniel BR, Young RR, Yardley DA
et al. (2016) Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2‐negative metastatic breast cancer: lack of response to HER2‐targeted therapy. Breast Cancer Research and Treatment
160, 41–49. 10.1007/s10549-016-3969-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-016-3969-7</ArticleId>
            <ArticleId IdType="pubmed">27632289</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
